Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

BUSERELIN ACETATE

Form:

4 of 4 products shown

All products: general benefit

Other products in the same Health Canada class (L02A, L02AE) — coverage varies; not interchangeable

  • Goserelin (Zoladex): general benefit
  • Leuprolide (Lupron Depot PDS): general benefit
  • Triptorelin (Trelstar (1 Month)): general benefit
  • Megestrol (Megace): general benefit, Not a benefit

Suprefact · DIN 02225166 · 1mg/mL · injection solution-5.5mL Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Suprefact · DIN 02225166 Manufacturer: Cheplapharm Arzneimittel GmbH; listing date 1999-01-08 Health Canada: Marketed since 2020-06-05 · brand SUPREFACT · ATC L02AE01 BUSERELIN · form Solution · route Subcutaneous · ingredients BUSERELIN (BUSERELIN ACETATE) 1 MG/ML · company Cheplapharm arzneimittel gmbh · schedule Prescription
Check this DIN again · Health Canada product record

Suprefact: Formulary list price $78.5873/unit (unit not stated in source; not the patient's cost)

Ministry pays: $78.5873 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43417 · Verify on the e-Formulary ↗ (DIN 02225166)

Source record
DIN 02225166: Suprefact Raw flags: sec3=Y Item: 100000075; group id 147; item number 0249; lccId None; manufacturer id CHE Source form: Inj Sol-5.5mL Pk; strength: 1mg/mL Recorded listing: General benefit Source prices (unrounded): $78.5873; ministry $78.5873 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02225166 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43417
Shortage status: resolved shortage (ended 2024-06-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02225166
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Suprefact Depot 2 Months · DIN 02228955 · 6.3mg · Implant Kit

General benefitDormant since 2025-11-01 · checked 2026-09-02 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Suprefact Depot 2 Months · DIN 02228955 Manufacturer: Cheplapharm Arzneimittel GmbH; listing date 1997-04-10 Health Canada: Dormant since 2025-11-01 · brand SUPREFACT DEPOT 2 MONTHS · ATC L02AE01 BUSERELIN · form Implant · route Subcutaneous · ingredients BUSERELIN (BUSERELIN ACETATE) 6.3 MG · company Cheplapharm arzneimittel gmbh · schedule Prescription
Check this DIN again · Health Canada product record

Suprefact Depot 2 Months: Formulary list price $929.2348/unit (unit not stated in source; not the patient's cost)

Ministry pays: $929.2348 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43499 · Verify on the e-Formulary ↗ (DIN 02228955)

Source record
DIN 02228955: Suprefact Depot 2 Months Raw flags: sec3=Y Item: 100000111; group id 147; item number 0247; lccId None; manufacturer id CHE Source form: Implant Kit; strength: 6.3mg Recorded listing: General benefit Source prices (unrounded): $929.2348; ministry $929.2348 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02228955 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43499
Shortage status: active shortage (reported 2024-11-01, last updated 2025-04-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02228955
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-11-01 — choose a marketed DIN from the same-category list.

Suprefact Depot 3 Months · DIN 02240749 · 9.45mg · Implant Kit

General benefitDormant since 2024-10-13 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Suprefact Depot 3 Months · DIN 02240749 Manufacturer: Cheplapharm Arzneimittel GmbH; listing date 2000-11-30 Health Canada: Dormant since 2024-10-13 · brand SUPREFACT DEPOT 3 MONTHS · ATC L02AE01 BUSERELIN · form Implant · route Subcutaneous · ingredients BUSERELIN (BUSERELIN ACETATE) 9.45 MG · company Cheplapharm arzneimittel gmbh · schedule Prescription
Check this DIN again · Health Canada product record

Suprefact Depot 3 Months: Formulary list price $1376.9938/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1376.9938 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64338 · Verify on the e-Formulary ↗ (DIN 02240749)

Source record
DIN 02240749: Suprefact Depot 3 Months Raw flags: sec3=Y Item: 100000151; group id 147; item number 0248; lccId None; manufacturer id CHE Source form: Implant Kit; strength: 9.45mg Recorded listing: General benefit Source prices (unrounded): $1376.9938; ministry $1376.9938 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240749 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64338
Shortage status: active shortage (reported 2023-10-24, last updated 2024-08-08) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240749
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2024-10-13 — choose a marketed DIN from the same-category list.

Suprefact · DIN 02225158 · 1mg/mL · Nas Sp-10mL Pk

General benefit; Health Canada lists this DIN as Cancelled post market since 2022-04-29 — choose a marketed DIN from the same-category list.Discontinued 2022-04-29 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-04-29 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-04-29 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Suprefact · DIN 02225158 Manufacturer: Cheplapharm Arzneimittel GmbH; listing date 1999-01-08 Health Canada: Cancelled post market since 2022-04-29 · brand SUPREFACT · ATC L02AE01 BUSERELIN · form Solution · route Nasal · ingredients BUSERELIN (BUSERELIN ACETATE) 100 MCG/ACT · company Cheplapharm arzneimittel gmbh · schedule Prescription
Check this DIN again · Health Canada product record

Suprefact: Formulary list price $85.5300/unit (unit not stated in source; not the patient's cost)

Ministry pays: $85.5300 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43416 · Verify on the e-Formulary ↗ (DIN 02225158)

Source record
DIN 02225158: Suprefact Raw flags: sec3=Y Item: 100000076; group id 147; item number 0250; lccId None; manufacturer id CHE Source form: Nas Sp-10mL Pk; strength: 1mg/mL Recorded listing: General benefit Source prices (unrounded): $85.5300; ministry $85.5300 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02225158 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43416
Shortage status: discontinued (2021-05-31, reported by CHEPLAPHARM ARZNEIMITTEL GMBH); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02225158
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-04-29 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

GOSERELIN ACETATE

· 2 products · General benefit · strengths: 3.6mg, 10.8mg · Depot Inj

LEUPROLIDE ACETATE

· 11 products · General benefit · strengths: 3.75mg, 7.5mg, 11.25mg, 22.5mg, 30mg, 3.75mg/Vial, 22.5mg/Vial, 45mg · Inj-Kit, Pd for Inj - Vial Pk, Pd Susp Inj-Pref Syr Kit

TRIPTORELIN PAMOATE

· 5 products · General benefit · strengths: 3.75mg/Vial, 11.25mg/Vial, 22.5mg/Vial · Inj Pd with Sterile Water-Vial Pk, Inj Pd-Vial Pk, SR Inj Pd with Sterile Water-Vial Pk

MEGESTROL ACETATE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 40mg, 160mg · Tab

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

ANASTROZOLE

· 17 products · General benefit · strengths: 1mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab

CAPECITABINE

· 15 products · General benefit · strengths: 150mg, 500mg · Tab

CHLORAMBUCIL

· 1 products · General benefit · strengths: 2mg · Tab

CYCLOPHOSPHAMIDE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg, 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE SUPREFACT® (buserelin acetate) is indicated for: Subcutaneous injection:  The palliative treatment (initial and maintenance treatment) of patients with hormone- dependent advanced carcinoma of the prostate gland (Stage D). Nasal solution:  The palliative treatment (maintenance treatment) of patients with hormone-dependent advanced carcinoma of the prostate gland (Stage D).  The treatment of endometriosis in patients who do not require surgery as primary therapy. The duration of treatment is usually six months and should not exceed nine months. SUPREFACT injection should be administered under the supervision of a health care professional. Geriatrics: No data is available. Page 3 of 57 Pediatrics (< 18 years of age): Experience with SUPREFACT for the management of endometriosis has been limited to women 18 years of age and older. https://pdf.hres.ca/dpd_pm/00056627.PDF PM date: June 2, 2020 Source product: SUPREFACT; DIN 02225166; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Suprefact Depot 2 Months · DIN 02228955 Shortage status: active shortage (reported 2024-11-01, last updated 2025-04-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02228955

Check this DIN again

Suprefact Depot 3 Months · DIN 02240749 Shortage status: active shortage (reported 2023-10-24, last updated 2024-08-08) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240749

Check this DIN again

Suprefact · DIN 02225158 Shortage status: discontinued (2021-05-31, reported by CHEPLAPHARM ARZNEIMITTEL GMBH); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02225158

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)